Rituximab: Review and clinical applications focusing on non-Hodgkin's lymphoma

Expert Review of Anticancer Therapy

Volumn 1, Issue 2, 2001, Pages 177-186

  King, Krista M ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CD20; Lymphoma; Mabthera; Monoclonal antibody; Rituximab

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; FLUDARABINE; METHOTREXATE; MITOXANTRONE; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; LARGE CELL LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; SIDE EFFECT; VOMITING;

EID: 0035557909     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.2.177     Document Type: Article

References (63)

1. Cancer statistics, 2001
2. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
3. Continuous cultures of fused cells secreting antibody of predefined specificity
4. Monoclonal antibody-based therapies of leukemia and lymphoma
5. Monoclonal antibody therapy of cancer
6. Monoclonal antibody therapies for lymphomas
7. Characterization of a human B lymphocyte-specific antigen
8. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
9. A unique cell surface antigen identifying lymphoid malignancies of B cell origin
10. CD20: A regulator of cell-cycle progression of B lymphocytes
11. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
12. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
13. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
14. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
15. Generation of monoclonal antibodies for in vivo approaches
16. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
17. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity
18. Rituximab: An insider's historical perspective
19. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
20. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
21. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
22. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
23. Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
24. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
25. IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
26. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
27. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of rituximab
28. A UK multicentre Phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
29. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
30. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study
31. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma
32. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
33. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-hodgkin lymphoma
34. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
35. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
36. Rituximab: Sustained remissions in patients with relapsed or refractory low grade or follicular non-Hodgkin's lymphoma
37. Phase II study of rituxan in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma
38. Molecular Responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma
39. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
40. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
41. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma
42. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
43. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
44. Rapid tumor lysis in a patients with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
45. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL
46. Rituximab dose-escalation trial in chronic lymphocytic leukemia
47. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
48. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders
49. Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity
50. Efficacy of rituximab in hairy cell leukemia treatment
51. Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?
52. Rituximab in cutaneous B-cell lymphoma: A report of two cases
53. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
54. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
55. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: A report of three cases
56. Treatment of post-transplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver lymphoproliferative disorder after solid organ transplantation?
57. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
58. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
59. Rituximab for the treatment of Type II mixed cryoglobulinemia
60. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia
61. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
62. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab